Skip to main content

The only migraine
medication that treats
and prevents all in one1,2

*Per IQVIA as oral brand in class (oral CGRP receptor antagonists): number one prescribed, number one in new prescriptions, and more neurologists selected as brand of choice

Ellie W Actual Nurtec ODT patient

The only medication proven:

FAST

  • ONE rapidly dissolving tablet that works quickly to resolve pain and return many patients back to normal activities in 1 hour1,3-5
  • Demonstrated preventive effect within 1 week for many patients6,‡

LASTS...

  • Treats or prevents for up to 48 hours at a time for many patients1,3,7
  • Reduction in mean monthly migraine days (MMDs) for many patients through 12 weeks of treatment1,2

see the data

Back to normal activities = return to normal function

‡Exploratory analysis. Subjects had ≥1 day of efficacy data in the observation period and in the first week of the double-blind treatment period.6

Study designs

For the acute indication, Nurtec ODT was evaluated in a multi‑center, double‑blind, randomized, placebo‑controlled study of 1351 patients (Nurtec ODT 75 mg, n=669; placebo, n=682), with co‑primary endpoints at 2 h for Nurtec ODT vs placebo: pain freedom (21% vs 11%, P<.001) and freedom from most bothersome symptoms (MBS; predefined as photophobia, phonophobia, or nausea; 35% vs 27%; P=.001).1

For the preventive indication, rimegepant 75 mg was evaluated in a multi‑center, double‑blind, randomized, placebo‑controlled study of 695 patients (rimegepant 75 mg, n=348; placebo, n=347) with the primary endpoint being change from baseline in the mean number of monthly migraine days during weeks 9‑12 (-4.3 vs -3.5, P=.01).1

A long-term open label safety study with 1800 patients evaluated rimegepant 75 mg dosed as needed for 52 weeks (N=1514) and dosed every other day plus as needed for 12 weeks (N=286).1,8

see full study design

Over 255 million insured individuals now have access to Nurtec ODT across all channels*,†

Coverage for 96% of your commercially-insured patients*

Find specific formulary coverage in your area.

Auto-locate

OR

*Managed Markets Insights & Technology LLC as of 1/10/2023 † UnitedHealthcare • Anthem • Aetna • Cigna

Ellie's Migraine Story

Ellie
Anytime I have a stressful exam or my period is coming up, I know I can count on Nurtec ODT to prevent my migraines.

Ellie W
Actual Nurtec ODT patient since 2018
Individual results may vary

How Greg took command of his migraines with Nurtec ODT

I wanted to leave my pain on the battlefield, but migraine attacks followed me home... Until Nurtec ODT changed all that.

Greg PFormer Green Beret Founder of Blue Ridge Safehouse nonprofit Actual Nurtec ODT patient since 2021 Individual results may vary

Nurtect® OneSource

Getting support and savings† for you and your patients has never been easier

learn more

†Eligible for some patients.

References: 1. Nurtec ODT. Package insert. Biohaven Pharmaceuticals Inc. 2. Croop R, Lipton RB, Kudrow D, et al. Oral rimegepant for preventive treatment of migraine: a phase 2/3, randomised, double-blind, placebo-controlled trial. Lancet. 2020;397(10268): 51-60. doi: 10.1016/S0140-6736(20)32544-7. 3. Croop R, Goadsby PJ, Stock DA, et al. Efficacy, safety, and tolerability of rimegepant orally disintegrating tablet for the acute treatment of migraine: a randomised, phase 3, double-blind, placebo-controlled trial. Lancet. 2019;394(10200):737-745. doi: 10.1016/S0140-6736(19)31606-X. 4. Data on File. RIM108. Pfizer Inc. 5. Lipton RB, Coric V, Stock EG, et al. Efficacy, safety, and tolerability of rimegepant 75 mg orally dissolving tablet for the acute treatment of migraine: a phase 3, double-blind, randomized, placebo-controlled trial (study 303). Abstract presented at: 61st Annual Scientific Meeting of the American Headache Society; Philadelphia, PA. Session IOR05; July 11, 2019. 6. Lipton RB, Croop R, Jensen CM, et al. Rapid Decrease in Migraine Days With Rimegepant: Results From a Post Hoc Analysis of a Phase 2/3, Randomized, Double-Blind, Placebo‑Controlled Trial. Virtual Poster presented at: American Headache Society 2021 Annual Meeting; June 3-6, 2021. 7. Data on File. RIM118. Pfizer Inc. 8. McGinley JS, L'Italien GJ, Thiry AC, et al. Rimegepant 75 mg results in reductions in monthly migraine days: Secondary analysis of a multicenter, open label, long-term safety study of rimegepant for the acute treatment of migraine. Virtual Poster presented at: American Academy of Neurology 2020 Annual Meeting; 2020.